Resistance Training (Most Important) 3-4 sessions per week, 45-60 minutes each Why resistance training is non-negotiable: Preserves and builds muscle during caloric deficit Increases daily calorie burn (muscle burns more at rest) Enhances insulin sensitivity Maximizes the muscle-building effects of elevated GH Optimal Training Split: Full Body 3x per week (Best for most people) Monday: Full body (squats, bench press, rows, etc.) Wednesday: Full body Friday: Full body Or Upper/Lower 4x per week (For advanced lifters) Monday: Upper body Tuesday: Lower body Thursday: Upper body Friday: Lower body Exercise Selection: Focus on compound movements that work multiple muscle groups: Lower Body: squats, deadlifts, lunges, leg press Upper Body: bench press, rows, pull-ups, overhead press Core: planks, ab wheel, hanging leg raises Cardio (Optional but Beneficial) 2-3 sessions per week, 20-30 minutes HIIT Cardio (Most Effective) High-intensity intervals synergize with elevated GH: Sprint intervals on bike, treadmill, or rowing machine Work: 30-60 seconds all-out effort Rest: 60-90 seconds easy pace Repeat 8-12 rounds Total time: 15-20 minutes Steady-State Cardio Lower intensity, longer duration: Walking, cycling, swimming Moderate pace (can hold conversation) 30-45 minutes Good for additional calorie burn without impacting recovery Recovery and Sleep Elevated GH dramatically improves recovery, but you still need: 7-9 hours sleep nightly peptides improve sleep quality, take advantage 1-2 complete rest days per week no structured exercise Active recovery walking, stretching, yoga on rest days Realistic Weight Loss Timeline on CJC-1295/Ipamorelin Setting realistic expectations prevents discouragement
increase energy
The lyophilised format supports stability in storage and transit, and orders are packaged securely for reliable shipping across Australia
In corticotrophs, POMC is mainly processed to the N-terminal glycopeptide, joining peptide, ACTH, and beta-LPH
Potential of these effects may be heightened in patients with breast cancer treated with hepatically metabolized chemotherapeutics (e.g., cyclophosphamide, paclitaxel, anthracyclines) or tyrosine kinase inhibitors in which drug-drug interaction-based elevation or lowering of enzyme activity can result in supra-therapeutic drug concentrations, accumulation of toxic metabolites and compromised detoxification of reactive oxygen species facilitating hepatocellular distress
